{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:48:57Z","timestamp":1786992537581,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jhep.2019.05.028","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T21:08:42Z","timestamp":1560200922000},"page":"660-665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Sofosbuvir\/velpatasvir for 12\u202fweeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7816-2929","authenticated-orcid":false,"given":"Sergio M.","family":"Borgia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Dearden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Shafran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziv","family":"Ben-Ari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Cramp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Foxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado Fernandez","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Dvory-Sobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu O.","family":"Osinusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Bruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8332-2122","authenticated-orcid":false,"given":"Javier","family":"Ampuero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shariq","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Lurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.05.028_b0005","unstructured":"World Health Organization (WHO). Hepatitis C Fact Sheet. Available from: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c (accessed 18 July 2018)."},{"issue":"12","key":"10.1016\/j.jhep.2019.05.028_b0010","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","article-title":"Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis","volume":"60","author":"Fabrizi","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.jhep.2019.05.028_b0015","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s10620-015-3918-z","article-title":"Incidence and progression of chronic kidney disease after hepatitis C seroconversion: results from ERCHIVES","volume":"61","author":"Rogal","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.jhep.2019.05.028_b0020","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","article-title":"The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies","volume":"14","author":"Fabrizi","year":"2007","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.1016\/j.jhep.2019.05.028_b0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100790","article-title":"Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.jhep.2019.05.028_b0030","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"Molnar","year":"2015","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jhep.2019.05.028_b0035","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jvh.12413","article-title":"A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection","volume":"22","author":"Park","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2019.05.028_b0040","unstructured":"AbbVie Inc. VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets, for oral use. US Prescribing Information. North Chicago, IL. Revised July 2016."},{"key":"10.1016\/j.jhep.2019.05.028_b0045","unstructured":"AbbVie Inc. MAVYRET TM (glecaprevir and pibrentasvir) tablets, for oral use. US Prescribing Information. Revised August 2018."},{"key":"10.1016\/j.jhep.2019.05.028_b0050","unstructured":"MSD International GmbH. ZEPATIER\u2122 (elbasvir and grazoprevir) tablets, for oral use. US Prescribing Information. Clonmel, Ireland. Revised January 2016."},{"key":"10.1016\/j.jhep.2019.05.028_b0055","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/tri.12799","article-title":"DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting","volume":"29","author":"Beinhardt","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2019.05.028_b0060","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2019.05.028_b0065","first-page":"2065","article-title":"Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure","volume":"32","author":"Dumortier","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jhep.2019.05.028_b0070","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3109\/23744235.2015.1078908","article-title":"Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency","volume":"47","author":"Hundemer","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.jhep.2019.05.028_b0075","series-title":"European Association for the Study of the Liver (EASL); 2016 13-17 April; Barcelona, Spain","first-page":"pS771","article-title":"Sofosbuvir-based, ribavirin-free regimens in patients with chronic hepatitis C and end-stage renal disease: a look at safety, tolerability and efficacy [Abstract SAT-164]","author":"Nazario","year":"2016"},{"key":"10.1016\/j.jhep.2019.05.028_b0080","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"issue":"Suppl","key":"10.1016\/j.jhep.2019.05.028_b0085","first-page":"396A","article-title":"Direct-acting antiviral treatment patterns among hepatitis C patients with advanced chronic kidney disease: a retrospective cohort study","volume":"62","author":"Singer","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.05.028_b0090","unstructured":"Gilead Sciences Ireland UC. Epclusa 400 mg\/100 mg film-coated tablets. Summary of Product Characteristics (SmPC). County Cork, Ireland. Revised September 2017."},{"key":"10.1016\/j.jhep.2019.05.028_b0095","unstructured":"Gilead Sciences Inc. EPCLUSA\u00ae (sofosbuvir and velpatasvir) tablets, for oral use. US Prescribing Information. Foster City, CA. Revised November 2017."},{"issue":"4","key":"10.1016\/j.jhep.2019.05.028_b0100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Dec Biometrika"},{"key":"10.1016\/j.jhep.2019.05.028_b9000","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroneterology"},{"key":"10.1016\/j.jhep.2019.05.028_b0105","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jhep.2019.05.028_b0110","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2019.05.028_b0115","series-title":"The liver meeting\u00ae 2017 \u2013 The 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2017 20\u201324 October; Washington, D. C","article-title":"Safety and efficacy of treatment with once-daily ledipasvir\/sofosbuvir (90\/400 mg) for 12 weeks in genotype 1 HCV-infected patients with severe renal impairment [Abstract 1587]","author":"Lawitz","year":"2017"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819303435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819303435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:35:51Z","timestamp":1759174551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819303435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0168827819303435"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.05.028","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofosbuvir\/velpatasvir for 12\u202fweeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}